PEDIATRIC INVESTIGATION PRACTICE
GUIDELINES AND POLICIES 2025
TERMINAL CERTIFICATION EVALUATION
COMPLETE QUESTIONS WITH FULL
SOLUTION ALREADY PASSED
⩥ What can support the assumptions of similarity in pediatric
extrapolation?
Answer: Existing data, published literature, expert panels, and previous
experiences with similar products.
⩥ What is the rationale for including pediatric subpopulations in adult
studies?
Answer: To gather more comprehensive data on drug effects across
different age groups.
⩥ What is the rationale for including adult subpopulations in pediatric
studies?
Answer: To ensure that the drug is safe and effective for both
populations.
⩥ What does ICH E11 (2000) Section 2.5 emphasize?
, Answer: The need for a rationale in selecting pediatric populations for
clinical studies.
⩥ How can statistical and pharmacometric methods optimize pediatric
drug development?
Answer: By integrating existing knowledge and extrapolating data from
other populations.
⩥ What is the potential impact of limiting the pediatric population for
study?
Answer: It could unnecessarily delay the development of medicines for
children.
⩥ What is the goal of pediatric drug development?
Answer: To deliver safe and effective medicines for children in a timely
manner.
⩥ Why is proactive planning essential in pediatric drug development?
Answer: It allows for the generation of meaningful data that can inform
treatment options.
⩥ What is the significance of understanding differences between
pediatric and reference populations?
GUIDELINES AND POLICIES 2025
TERMINAL CERTIFICATION EVALUATION
COMPLETE QUESTIONS WITH FULL
SOLUTION ALREADY PASSED
⩥ What can support the assumptions of similarity in pediatric
extrapolation?
Answer: Existing data, published literature, expert panels, and previous
experiences with similar products.
⩥ What is the rationale for including pediatric subpopulations in adult
studies?
Answer: To gather more comprehensive data on drug effects across
different age groups.
⩥ What is the rationale for including adult subpopulations in pediatric
studies?
Answer: To ensure that the drug is safe and effective for both
populations.
⩥ What does ICH E11 (2000) Section 2.5 emphasize?
, Answer: The need for a rationale in selecting pediatric populations for
clinical studies.
⩥ How can statistical and pharmacometric methods optimize pediatric
drug development?
Answer: By integrating existing knowledge and extrapolating data from
other populations.
⩥ What is the potential impact of limiting the pediatric population for
study?
Answer: It could unnecessarily delay the development of medicines for
children.
⩥ What is the goal of pediatric drug development?
Answer: To deliver safe and effective medicines for children in a timely
manner.
⩥ Why is proactive planning essential in pediatric drug development?
Answer: It allows for the generation of meaningful data that can inform
treatment options.
⩥ What is the significance of understanding differences between
pediatric and reference populations?
